Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Substance Abuse, Domestic Violence, HIV/AIDS
Interventions: HoMBReS intervention, Families Talking Together (FTT), Diabetes Prevention Intervention; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Male only
Enrollment: 244 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Quality of Life
Interventions: Extra Care (EC) Intervention, Usual Care (UC); Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Osteoarthritis, Pain
Interventions: Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Celecoxib 100 mg, Celecoxib 100 mg Matching Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 32
States / cities: Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Hepatitis C
Interventions: Not listed
Lead sponsor: Hologic, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 33
States / cities: North Little Rock, Arkansas • Bakersfield, California • Rialto, California + 26 more

Conditions: Non-Hodgkin's Lymphoma
Interventions: Rituximab, bortezomib; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Chicago, Illinois • Philadelphia, Pennsylvania

Conditions: Alveolitis, Fibrosing, Fibrosis, Pulmonary, Hypertension, Pulmonary
Interventions: sildenafil; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Tipranavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 38
States / cities: Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 33 more

Conditions: Head and Neck Cancer, Precancerous Condition
Interventions: cetuximab, cisplatin, IMRT; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2025
U.S. locations: 183
States / cities: Anchorage, Alaska • Auburn, California • Burbank, California + 152 more

Conditions: Localized Prostate Cancer
Interventions: Aquablation Therapy, Radical Prostatectomy; Device · Procedure
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 26
States / cities: Chandler, Arizona • Mesa, Arizona • Los Angeles, California + 22 more

Conditions: Chronic Migraine
Interventions: Atogepant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more

Conditions: Diabetes, Diabetes Mellitus, Type 2, Renal Impairment
Interventions: semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee

Conditions: HIV Infections
Interventions: Antiretroviral Regimens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 67
States / cities: Fresno, California • Mill Valley, California • Oakland, California + 32 more

Conditions: Autism Spectrum Disorders
Interventions: Arbaclofen; Drug
Lead sponsor: Seaside Therapeutics, Inc.; Industry
Eligibility: 5 Years to 21 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 21 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 61
States / cities: Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more

Conditions: Type 2 Diabetes Mellitus
Interventions: tirzepatide, Dulaglutide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Mobile, Alabama • Anaheim, California • Fresno, California + 30 more

Conditions: Corneal Transplant Failure
Interventions: Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking; Procedure
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: Irvine, California • Los Angeles, California • San Francisco, California + 9 more

Conditions: Dravet Syndrome
Interventions: ETX101; Drug
Lead sponsor: Encoded Therapeutics; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 11
States / cities: San Francisco, California • Aurora, Colorado • Miami, Florida + 8 more

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab; Radiation · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 296
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more

Conditions: Arthritis, Osteoarthritis, Osteoarthritis, Hip
Interventions: tanezumab, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 99
States / cities: Mobile, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 74 more

Conditions: Alzheimer's Disease
Interventions: ACC-001 3 μg/ QS-21 50 μg, ACC-001 10 μg/ QS-21 50 μg, Placebo- Phosphate buffered saline (PBS); Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 40
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 17 more

Conditions: Pain
Interventions: Advil PM Liqui-Gels Minis, Advil PM Liqui-Gels; Drug
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Excessive Sleepiness, Shift-work Disorder
Interventions: Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 44
States / cities: Auburn, Alabama • Cullman, Alabama • Chandler, Arizona + 37 more

Conditions: Hepatitis C Virus
Interventions: Velpatasvir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Saint Paul, Minnesota + 1 more

Conditions: COVID-19
Interventions: Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens; Other
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years and older
Enrollment: 1,753 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Vestavia Hills, Alabama • Mesa, Arizona • Fair Oaks, California + 12 more

Search by objective public record fields.

Hispanic Men Building Respect Education and Safety/ HoMBRES Manteniendo Respeto, Educacion y Seguridad.

Mohs Surgery: Patient Satisfaction & Quality of Life (QOL)

Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007

Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

WATER IV Prostate Cancer

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Effect of Renal Impairment on the Pharmacokinetics of NN9535

Effects of Two Anti-HIV Drug Regimens on Quality of Life and Health Care Use Among SMART Study Participants

Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Tanezumab in Osteoarthritis Of The Hip

Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease

A Bioequivalence Study of Advil PM Liqui-Gels Minis (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) Compared to the Current Marketed Advil PM Liqui-Gels (Ibuprofen/Diphenhydramine Hydrochloride 200 mg/25 mg) in Healthy Adult Subjects Under Fasted Conditions

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Study to Evaluate the Pharmacokinetics of Velpatasvir in Participants With Normal Renal Function and Severe Renal Impairment

Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)